BioInvent Selected to The Leukemia & Lymphoma Society's Therapy Acceleration Program and Receives $3 million Strategic Equity Investment Seite 1

17.01.2023 - Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's LymphomaSupports also clinical development of BI-1808 in cutaneous T-cell lymphomaLLS TAP is a strategic funding initiative to accelerate ... Seite 1

Related Keywords

Martin Welschof ,Leukemia Lymphoma Society Therapy Acceleration Program ,Leukemia Lymphoma Society ,Bioinvent International Ab Nasdaq Stockholm ,Therapy Acceleration Program ,Bioinvent International ,Nasdaq Stockholm ,Lymphoma Society ,Acceleration Program ,Lore Gruenbaum ,Vice President ,